CAN04 + pembrolizumab + carboplatin + pemetrexed

This is a **combination therapy** consisting of **CAN04 (nadunolimab)**, **pembrolizumab**, **carboplatin**, and **pemetrexed**. - **CAN04 (nadunolimab)** is a fully humanized monoclonal antibody targeting the interleukin-1 receptor accessory protein (IL1RAP) on tumor cells. It acts via stimulating natural killer (NK) cells (antibody-dependent cellular cytotoxicity, ADCC) and blocking interleukin-1 (IL-1α and IL-1β) signaling, thus counteracting tumor inflammation and resistance to chemotherapy[1][5][7]. - **Pembrolizumab** is a humanized IgG4-kappa monoclonal antibody against PD-1, functioning as an immune checkpoint inhibitor. It blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), enhancing T-cell anti-tumor activity[2][8]. - **Carboplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks and inhibits DNA synthesis, causing cancer cell death. - **Pemetrexed** is a multi-targeted antifolate antineoplastic agent that primarily inhibits thymidylate synthase and other enzymes involved in folate metabolism, suppressing DNA and RNA synthesis. This combination is under clinical investigation for use in **solid tumors**, including non-small cell lung cancer (NSCLC), especially in patients relapsed or refractory to standard treatments[1][3][7]. Key rationale includes CAN04's immunomodulatory effect synergizing with chemotherapy and checkpoint blockade.

Other names

nadunolimab + pembrolizumab + carboplatin + pemetrexed